SBWire

Global Market Direct's pharmaceuticals report, "Torrent Pharmaceuticals Limited - Product Pipeline Review - 2013" provides data on the Torrent Pharmaceuticals Limited's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "EpiZyme, Inc. - Product Pipeline Review - 2013" provides data on the EpiZyme, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Birch Pollen Allergy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Birch Pollen Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Birch Pollen Allergy. Birch Pollen Allergy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Market Direct's pharmaceuticals report, "Pluristem Therapeutics Inc. - Product Pipeline Review - 2013" provides data on the Pluristem Therapeutics Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Retinitis Pigmentosa (Retinitis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa (Retinitis). Retinitis Pigmentosa (Retinitis) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Markets Direct's, 'Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Exocrine Pancreatic Insufficiency, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Exocrine Pancreatic Insufficiency. Exocrine Pancreatic Insufficiency - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Market Direct's pharmaceuticals report, "Antoxis Limited - Product Pipeline Review - 2013" provides data on the Antoxis Limited's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Genosco - Product Pipeline Review - 2013" provides data on the Genosco's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Physica Pharma - Product Pipeline Review - 2013" provides data on the Physica Pharma's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Apitope International NV - Product Pipeline Review - 2013" provides data on the Apitope International NV's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Delenex Therapeutics AG - Product Pipeline Review - 2013" provides data on the Delenex Therapeutics AG's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Bladder cancer is a urologic malignancy arising from the epithelial lining of the urinary bladder. Although it is the ninth most common cancer worldwide in men and women, with the highest recurrence rate of any malignancy, relatively little is known about its etiology. There has been little development over the past 20 years in bladder cancer, with a huge void of unmet met needs which are yet to be filled.

Anabol Pharmacy has established its name as one of the most reputed and trustworthy online stores that offers anabolic steroids in both tablet and injectable form at the best prices. The company offers various supplements, including Anadrol 50, Anavar, Arimidex, Clenbuterol, Clomid, Deca Durabolin, Dianabol, Equipose, Durabolin, Novaldex, Proviron, Sustanon, Testosterone Cypionate, and Winstrol. Anabol Pharmacy offers great deals on its entire range of products.

The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

Dr. Joel Wallach, a naturopathic doctor, is offering his therapeutic services as well as his supplementary vitamins and minerals to the public via his website http://youngevityliving.com. Dr. Wallach is originally a DVM and has spent more than 40 years observing and researching the effects of nutritional supplements on animal health. He ventured into Naturopathy and became a Naturopathic Physician in 1982.

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

GlobalData has released its pharma report, "PharmaPoint: Atopic Dermatitis - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Atopic Dermatitis Market. The report identifies and analyses the key companies shaping and driving the global Atopic Dermatitis market. The report provides insight into the competitive Atopic Dermatitis landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.

A new, all-natural nutritional supplement that has powerful anti-inflammatory and anti-viral properties is now available on Amazon.

Global Market Direct's pharmaceuticals report, "Adamas Pharmaceuticals, Inc. - Product Pipeline Review - 2013" provides data on the Adamas Pharmaceuticals, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.